L. Scott Clark

Statistics

Publications

Citations

199

H-Index

Active since

2000

Affiliations

Tris Pharma (United States)(Current)

University of North Carolina at Chapel Hill

North Carolina State University

UNC Lineberger Comprehensive Cancer Center

L. Scott Clark is an author at Tris Pharma (United States) specializing in pharmacology, chemotherapy pharmacogenomics, and drug-induced peripheral neuropathy.

Publications per year

2000–2014

Publications

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

Daniel L. Hertz, S Roy, Alison A. Motsinger‐Reif et al. · Annals of Oncology · 2013 · 113 citations · Full text

Medicine, Oncology, Pharmacology +14

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Daniel L. Hertz, Siddharth Roy, John Jack et al. · Breast Cancer Research and Treatment · 2014 · 44 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial

Michael Murphy, Margaret E. Beaman, L. Scott Clark et al. · Pharmacogenetics · 2000 · 42 citations

Medicine, Pharmacokinetics, Pharmacology +14

1–3 of 3